Ticagrelor

Generic Name
Ticagrelor
Brand Names
Brilinta, Brilique
Drug Type
Small Molecule
Chemical Formula
C23H28F2N6O4S
CAS Number
274693-27-5
Unique Ingredient Identifier
GLH0314RVC
Background

Ticagrelor, or AZD6140, was first described in the literature in 2003. Ticagrelor is an ADP derivative developed for its P2Y receptor antagonism. Unlike clopidogrel, ticagrelor is not a prodrug. It is marketed by Astra Zeneca as Brilinta in the US and Brilique or Possia in the EU,.

Ticagrelor was granted EMA approval on 3 December 2010.

Ticagrelor was granted FDA approval on 20 July 2011.

Indication

Ticagrelor is indicated to reduce the risk of cardiovascular death, myocardial infarction, and stroke in patients with acute coronary syndrome or a history of myocardial infarction. Ticagrelor is also indicated to reduce the risk of a first myocardial infarction or stroke in high risk patients with coronary artery disease.

Associated Conditions
Cardiovascular Mortality, Myocardial Infarction, Stroke, Thrombosis (Stent Thrombosis)
Associated Therapies
-
Clinical Trials
Related News

Comparative Efficacy of Ticagrelor Versus Aspirin on Blood Viscosity in Peripheral Artery Disease Patients With Type 2 Diabetes

First Posted Date
2014-12-25
Last Posted Date
2022-03-21
Lead Sponsor
Icahn School of Medicine at Mount Sinai
Target Recruit Count
70
Registration Number
NCT02325466
Locations
🇺🇸

Icahn School of Medicine at Mount Sinai, New York, New York, United States

Impact of Renal Function on Ticagrelor-Induced Antiplatelet Effects in Coronary Artery Disease Patients

First Posted Date
2014-12-24
Last Posted Date
2017-12-14
Lead Sponsor
Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia
Target Recruit Count
80
Registration Number
NCT02323971
Locations
🇪🇸

Hospital Universitario Virgen de la Arrixaca, Murcia, Spain

Comparison of Low-Dose, Standard-Dose Ticagrelor and Clopidogrel for Inhibition of Platelet Reactivity in Patients With Acute Coronary Syndromes

Phase 2
Completed
Conditions
Acute Coronary Syndrome
Interventions
Drug: ticagrelor
Drug: clopidogrel
First Posted Date
2014-12-18
Last Posted Date
2017-06-16
Lead Sponsor
Seung-Jung Park
Target Recruit Count
65
Registration Number
NCT02319941
Locations
🇰🇷

Asan Medical Center, Seoul, Songpa-gu, Korea, Republic of

A Study to Compare the Safety of Rivaroxaban Versus Acetylsalicylic Acid in Addition to Either Clopidogrel or Ticagrelor Therapy in Participants With Acute Coronary Syndrome

First Posted Date
2014-11-18
Last Posted Date
2017-12-26
Lead Sponsor
Janssen Research & Development, LLC
Target Recruit Count
3037
Registration Number
NCT02293395

Ticagrelor Pharmacokinetics in NSTEMI

Completed
Conditions
Myocardial Infarction
Interventions
Drug: Ticagrelor
First Posted Date
2014-11-17
Last Posted Date
2016-05-23
Lead Sponsor
Karolinska University Hospital
Target Recruit Count
63
Registration Number
NCT02292277
Locations
🇸🇪

Södersjukhuset, Stockholm, Sweden

Study of Ticagrelor Versus Aspirin Treatment in Patients With Myocardial Injury Post Major Non-cardiac Surgery

Phase 4
Terminated
Conditions
Myocardial Injury
Interventions
Drug: ticagrelor
Drug: aspirin
First Posted Date
2014-11-14
Last Posted Date
2017-02-09
Lead Sponsor
The Cleveland Clinic
Target Recruit Count
6
Registration Number
NCT02291419
Locations
🇺🇸

University of South Florida, Tampa, Florida, United States

🇺🇸

Cleveland Clinic, Cleveland, Ohio, United States

🇺🇸

VA North Texas Health Care System, Dallas, Texas, United States

and more 21 locations

Switching From Ticagrelor to Clopidogrel in Patients With Coronary Artery Disease

Phase 4
Completed
Conditions
Coronary Artery Disease
Interventions
Drug: Clopidogrel
Drug: Ticagrelor
First Posted Date
2014-11-11
Last Posted Date
2020-09-16
Lead Sponsor
University of Florida
Target Recruit Count
87
Registration Number
NCT02287909
Locations
🇺🇸

University of Florida, Jacksonville, Florida, United States

High "on Treatment" Platelet Reactivity in the Intensive Care Unit

First Posted Date
2014-11-07
Last Posted Date
2019-08-20
Lead Sponsor
Medical University of Vienna
Target Recruit Count
200
Registration Number
NCT02285751
Locations
🇦🇹

General Hospital, Vienna, Austria

Effect of Ticagrelor on Adenosine-Induced Coronary Flow Reserve in Patients With Microvascular Angina

Phase 4
Conditions
Microvascular Angina
Interventions
Drug: ticagrelor
First Posted Date
2014-11-05
Last Posted Date
2014-11-06
Lead Sponsor
Second Xiangya Hospital of Central South University
Target Recruit Count
140
Registration Number
NCT02284048

NIRS Ticagrelor Evaluation

Phase 4
Completed
Conditions
Coronary Artery Disease
Interventions
Drug: Ticagrelor
First Posted Date
2014-11-04
Last Posted Date
2021-04-08
Lead Sponsor
Medstar Health Research Institute
Target Recruit Count
30
Registration Number
NCT02282332
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy